Aurora Cannabis (ACB) EBITDA (2017 - 2026)

Aurora Cannabis (ACB) has reported EBITDA for 10 consecutive years, with $7.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 73.26% year-over-year to $7.3 million in Q2 2026; TTM through Jun 2026 was $27.1 million, a 29.55% decrease from a year earlier, with the FY2026 full-year figure at -$33.8 million, down 1048.62% from the prior year.
• EBITDA was $7.3 million for Q2 2026 at Aurora Cannabis, up from $3.0 million in the prior quarter.
• Over five years, EBITDA peaked at $19.4 million in Q4 2024 and troughed at -$128.8 million in Q4 2022.
• A 5-year average of -$14.0 million and a median of $2.9 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 764.55% in 2022 and jumped 686.33% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$128.8 million in 2022, then jumped by 104.01% to $5.2 million in 2023, then surged by 275.18% to $19.4 million in 2024, then retreated by 27.67% to $14.0 million in 2025, then slumped by 48.05% to $7.3 million in 2026.
• The last three EBITDA figures came in at $7.3 million (Q2 2026), $3.0 million (Q1 2026), and $14.0 million (Q4 2025), per Business Quant data.